12:00 AM
 | 
May 14, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Tofacitinib regulatory update

FDA's Arthritis Advisory Committee voted 8-2 in favor of recommending approval of tofacitinib from Pfizer to treat moderately to severely active rheumatoid arthritis in patients who have had inadequate response to >=1 DMARDs. Panelists also voted 10-0 that the oral pan-Janus kinase (JAK) inhibitor showed substantial evidence of efficacy...

Read the full 224 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >